IT201600079773A1 - Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. - Google Patents

Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.

Info

Publication number
IT201600079773A1
IT201600079773A1 IT102016000079773A IT201600079773A IT201600079773A1 IT 201600079773 A1 IT201600079773 A1 IT 201600079773A1 IT 102016000079773 A IT102016000079773 A IT 102016000079773A IT 201600079773 A IT201600079773 A IT 201600079773A IT 201600079773 A1 IT201600079773 A1 IT 201600079773A1
Authority
IT
Italy
Prior art keywords
compositions
derivatives
preparation
hyaluronic acid
sulfate
Prior art date
Application number
IT102016000079773A
Other languages
English (en)
Inventor
Matteo Bevilacqua
Original Assignee
Matteo Bevilacqua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matteo Bevilacqua filed Critical Matteo Bevilacqua
Priority to IT102016000079773A priority Critical patent/IT201600079773A1/it
Priority to PCT/EP2017/069167 priority patent/WO2018019996A1/en
Publication of IT201600079773A1 publication Critical patent/IT201600079773A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT102016000079773A 2016-07-29 2016-07-29 Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni. IT201600079773A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102016000079773A IT201600079773A1 (it) 2016-07-29 2016-07-29 Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.
PCT/EP2017/069167 WO2018019996A1 (en) 2016-07-29 2017-07-28 Compositions containing hyaluronic acid oligosaccharides (ha4), chondroitin sulfate (cs2-4), and heparan sulfate (hs2-4), pentacyclic triterpenes and derivatives for curative medical use, and method for preparing the compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000079773A IT201600079773A1 (it) 2016-07-29 2016-07-29 Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.

Publications (1)

Publication Number Publication Date
IT201600079773A1 true IT201600079773A1 (it) 2018-01-29

Family

ID=58159222

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102016000079773A IT201600079773A1 (it) 2016-07-29 2016-07-29 Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.

Country Status (2)

Country Link
IT (1) IT201600079773A1 (it)
WO (1) WO2018019996A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210015830A1 (en) * 2017-12-28 2021-01-21 Suntory Holdings Limited Composition for inhibiting reactive oxygen species production
IT202200004340A1 (it) * 2022-03-08 2023-09-08 Pharmaceutica San Marco S R L Composizione o associazione di composti preferibilmente per l’uso nel trattamento di malattie nervose in particolare neurodegenerative, metodo per la preparazione di tale composizione o associazione di composti e suoi impieghi

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009637A2 (en) * 2000-07-28 2002-02-07 Sinclair Pharmaceuticals Limited Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
EP1611893A1 (en) * 2003-03-25 2006-01-04 Seikagaku Corporation Remedy for nerve damage
US20060239987A1 (en) * 2005-04-22 2006-10-26 Robert Foster Nutritional composition and methods of making and using same
EP1767211A1 (en) * 2005-09-26 2007-03-28 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
EP1994934A1 (en) * 2006-12-05 2008-11-26 Glycoscience Laboratories, Inc. Therapeutic agent for degenerative arthritis
EP2106798A1 (en) * 2008-04-02 2009-10-07 Nestec S.A. Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair
WO2014076643A1 (en) * 2012-11-13 2014-05-22 ZAGGIA, Guerrino Compound particularly for treating depression and anxiety
WO2015088198A1 (ko) * 2013-12-09 2015-06-18 (주)뉴메딕 지속성을 갖는 히알루론산 겔 조성물

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009637A2 (en) * 2000-07-28 2002-02-07 Sinclair Pharmaceuticals Limited Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
EP1611893A1 (en) * 2003-03-25 2006-01-04 Seikagaku Corporation Remedy for nerve damage
US20060239987A1 (en) * 2005-04-22 2006-10-26 Robert Foster Nutritional composition and methods of making and using same
EP1767211A1 (en) * 2005-09-26 2007-03-28 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
EP1994934A1 (en) * 2006-12-05 2008-11-26 Glycoscience Laboratories, Inc. Therapeutic agent for degenerative arthritis
EP2106798A1 (en) * 2008-04-02 2009-10-07 Nestec S.A. Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair
WO2014076643A1 (en) * 2012-11-13 2014-05-22 ZAGGIA, Guerrino Compound particularly for treating depression and anxiety
WO2015088198A1 (ko) * 2013-12-09 2015-06-18 (주)뉴메딕 지속성을 갖는 히알루론산 겔 조성물
EP3081232A1 (en) * 2013-12-09 2016-10-19 New Medic Co., Ltd. Hyaluronic acid gel composition having sustained release property

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAGE MADOKA ET AL: "Hyaluronan tetrasaccharides stimulate ceramide production through upregulated mRNA expression of ceramide synthesis-associated enzymes", ARCHIVES OF DERMATOLOGICAL RESEARCH, SPRINGER, INTERNATIONAL, BERLIN, DE, vol. 308, no. 2, 28 December 2015 (2015-12-28), pages 95 - 101, XP035878866, ISSN: 0340-3696, [retrieved on 20151228], DOI: 10.1007/S00403-015-1615-6 *
MADOKA KAGE ET AL: "Permeation of hyaluronan tetrasaccharides through hairless mouse skin: an in vitro and in vivo study", ARCHIVES OF DERMATOLOGICAL RESEARCH ; FOUNDED IN 1869 AS ARCHIV FÜR DERMATOLOGIE UND SYPHILIS, SPRINGER, BERLIN, DE, vol. 305, no. 1, 28 June 2012 (2012-06-28), pages 69 - 77, XP035156491, ISSN: 1432-069X, DOI: 10.1007/S00403-012-1252-2 *
WANG JUN ET AL: "Hyaluronan Tetrasaccharide Exerts Neuroprotective Effect and Promotes Functional Recovery After Acute Spinal Cord Injury in Rats", NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 40, no. 1, 6 November 2014 (2014-11-06), pages 98 - 108, XP035433654, ISSN: 0364-3190, [retrieved on 20141106], DOI: 10.1007/S11064-014-1470-4 *

Also Published As

Publication number Publication date
WO2018019996A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
CY1120885T1 (el) Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112016003053A2 (pt) micropartículas de células tronco e mirna
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
BR112017010426A2 (pt) processo para preparar um pó inorgânico poroso.
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo
EP3773900A4 (en) HINOKITIOL ANALOGUES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
EP3409292A4 (en) AQUEOUS STABILIZED COMPOSITION COMPRISING CHONDROITIN SULFATE AND HYALURONIC ACID
BR112018006870A2 (pt) nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas
BR112018003455A2 (pt) composição ou composição farmacêutica e uso da composição
EP3398971A4 (en) OLIGOSACCHARIDE OF SULPHATED HEPARIN AND PREPARATION METHOD AND APPLICATION THEREOF
IT201600079773A1 (it) Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.
EP3311809A4 (en) USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
EA201691246A1 (ru) Комбинация гликозаминогликанов и циклодекстринов
IT201700110784A1 (it) Composizioni farmaceutiche contenenti Acido Ialuronico e Carnosina e relativo uso